| 3.4 0.01 (0.29%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.53 | 1-year : | 5.3 |
| Resists | First : | 3.88 | Second : | 4.53 |
| Pivot price | 3.45 |
|||
| Supports | First : | 2.73 | Second : | 2.02 |
| MAs | MA(5) : | 3.42 |
MA(20) : | 3.19 |
| MA(100) : | 1.75 |
MA(250) : | 1.67 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 66.5 |
D(3) : | 69.4 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 5.38 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PYXS ] has closed above bottom band by 43.9%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.47 - 3.5 | 3.5 - 3.52 |
| Low: | 3.22 - 3.24 | 3.24 - 3.26 |
| Close: | 3.37 - 3.41 | 3.41 - 3.44 |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Mon, 27 Oct 2025
Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors - TipRanks
Mon, 27 Oct 2025
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment - TipRanks
Fri, 17 Oct 2025
Millennium Management LLC Reduces Stake in Pyxis Oncology Inc - GuruFocus
Tue, 14 Oct 2025
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Nasdaq
Thu, 09 Oct 2025
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com
Thu, 09 Oct 2025
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 23.3 (%) |
| Held by Institutions | 35.4 (%) |
| Shares Short | 4,250 (K) |
| Shares Short P.Month | 4,360 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | -676.1 % |
| Return on Assets (ttm) | -31.3 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -2.14 |
| PEG Ratio | 0 |
| Price to Book value | 2.41 |
| Price to Sales | 74.77 |
| Price to Cash Flow | -2.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|